Uppsala University, Department of Medical Cell Biology, Biomedicum, P.O. Box 571, S-751 23, Uppsala, Sweden.
Expert Opin Investig Drugs. 2012 Nov;21(11):1743-50. doi: 10.1517/13543784.2012.724398. Epub 2012 Sep 24.
The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how.
It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/amyloid properties, in for example systemic sclerosis and mouse models for Alzheimer's disease, the present review will discuss the possibility that Imatinib acts, at least in part, by ameliorating islet hyalinization and its consequences in the pathogenesis of Type-2 diabetes.
A better understanding of how Imatinib counteracts Type-2 diabetes will possibly help to clarify the pathogenic role of islet amyloid and fibrosis, and hopefully lead to improved treatment of the disease.
小分子酪氨酸激酶抑制剂甲磺酸伊马替尼（格列卫）可预防糖尿病，但具体机制尚不清楚。
有观点认为胰岛淀粉样变和纤维沉积会促进β细胞衰竭和死亡，导致 2 型糖尿病。已知伊马替尼具有抗纤维化/淀粉样变特性，例如在系统性硬化症和阿尔茨海默病的小鼠模型中，本综述将讨论伊马替尼通过改善 2 型糖尿病发病机制中的胰岛玻璃样变及其后果发挥作用的可能性。
更好地了解伊马替尼如何对抗 2 型糖尿病，可能有助于阐明胰岛淀粉样变和纤维化的致病作用，并有望改善该疾病的治疗。
